Bristol Pays Out $200m For Agenus' Preclinical Bispecific TIGIT
Agenus president Jennifer Buell talked to Scrip about partnering with Bristol and the dual nature approach of AGEN1777.
You may also be interested in...
Merck’s Keytruda and BMS’s Opdivo could be tough competitors in esophageal cancer, but the Novartis/BeiGene partnership also has an anti-TIGIT drug up its sleeve.
Tiragolumab missed several endpoints in a Phase III metastatic SCLC study, and hopes now rest on its success in NSCLC which presents the bigger market opportunity for the lead candidate in this closely watched new drug class.
Latest option deal with Swiss major solidifies BeiGene’s front-runner position in PD-1 combination therapy with novel antibodies.